Press release

20 Aug, 2020  ·  Regulatory information

Cantargia publishes half year report

Cantargia AB’s (”Cantargia”) half year report for the period January until June 2020 is now available on the company’s web page

 Significant events in the second quarter

  • In April, it was announced that the ongoing COVID-19 pandemic, resulted in a three month delay of Cantargia’s CANFOUR trial.
  • In May, the US Food and Drug Administration (FDA) approved Cantargia’s IND application from April for the start of clinical trials in the US with CAN04 and immunotherapy.
  • At the 2020 AACR Annual Meeting in June, new preclinical results were presented that support the combination of Cantargia’s CAN04 antibody with platinum-based chemotherapy for cancer therapy.

Financial information

First half 2020 (1 Jan 2020 – 30 Jun 2020)
  •  Net sales: SEK 0 (0) million
  •  Operating loss: SEK -77.6 (-48.9) million
  •  Loss after tax: SEK -77.0 (-48.6) million
  •  Loss per share: before and after dilution, SEK -0.89 (-0.70)
  •  Equity/assets ratio: 93 (91) per cent
  •  Cash and cash equivalents: SEK 248.3 (59.2) million
  •  Short-term investments: SEK 210.0 (160.0) million
Second quarter 2020 (1 Apr 2020 – 30 Jun 2020)
  •  Net sales: SEK 0 (0) million
  •  Operating loss: SEK -37.7 (-25.2) million
  •  Loss after tax: SEK -37.1 (-25.0) million
  •  Loss per share, before and after dilution: SEK -0.41 (-0.34)

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60

This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on August 20, 2020.

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied in the clinical phase I/IIa CANFOUR study with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is focused on combination therapies, but also includes a monotherapy arm. Positive interim data from the combination therapies were presented in December 2019. Cantargia’s second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at

2020-08-20 Interim report Q2 PR Eng final.pdf